Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Vivos Therapeutics, Inc.

NASDAQ: VVOS · Industrial Applications and Services · 6 alerts · CIK 1716166

Share price
$0.0822Close, Nov 16
Market cap
$1.14M
Shares outstanding
13.89MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Vivos Therapeutics, Inc. filings on SEC EDGAR ↗

6:04 AM ET 8-K
Financial Results

Vivos Therapeutics Financial Results

Vivos Therapeutics reported Q3 2026 financial results, highlighting a 24% sequential revenue increase to $6.4 million and an 18% year-over-year improvement in operating loss. The company successfully regained compliance with Nasdaq's stockholders' equity requirement following debt-for-equity exchanges and the closing of its SOD Sciences transaction.

Term
Q3 2026

“During the third quarter of 2026, we took decisive steps to reduce costs and strengthen our balance sheet. Our operating loss improved 18% compared to the prior-year quarter, general and administrative and sales and marketing expenses together declined by $1.6 million, and we have now eliminated an estimated $5 million or more in annual operating costs, with further efficiencies underway.”

Kirk Huntsman, Vivos’ Chairman and Chief Executive Officer

“We are also pursuing a number of clinical initiatives at our SCN and SAMC centers, including EEG testing and treatment for insomnia and other non-OSA sleep disorders, the distribution and set-up of PAP and CPAP treatments, and remote patient monitoring of CPAP users, together with the renegotiation of our payer contracts. We expect these initiatives to contribute to revenue and margins beginning in the fourth quarter of 2026 and increasingly throughout 2027.”

Kirk Huntsman, Vivos’ Chairman and Chief Executive Officer
6:32 PM ET 10-Q
Financial Results

Vivos Therapeutics Q3 2026 Results: Net Loss of $1.95M, Loss Narrows

Vivos Therapeutics is transitioning from a legacy dentist-focused model to a medical-provider focused sales and distribution model, highlighted by the acquisition of The Sleep Center of Nevada and a transaction with SOD Sciences. The company faces significant challenges regarding its Nasdaq listing requirements and the integration of its new business model while managing substantial indebtedness.

Key figure
Net loss $1.95M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.